
To estimate the effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the UK variant of concern B.1.1.7), admissions to hospital, and deaths.
|
https://www.bmj.com/content/373/bmj.n1088.full |
|
13 May 2021, BMJ |
|
Vaccine Effectiveness |
|
Test negative case-control study |
|
England |
|
Level IV: case-control study |
|
To estimate the effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the UK variant of concern B.1.1.7), admissions to hospital, and deaths. |
|
In the test-negative case control study, they included 156 930 adults aged 70 years and older who reported symptoms of covid-19.
This study provides preliminary real-world evidence for the efficacy of the Pfizer-BioNTech BNT162b2 and Oxford-Asta-Zeneca ChAdOx1-S vaccines against symptomatic covid-19, hospitalizations, and death in older people in England. |
Results |
|
|
-Vaccination with either BNT162b2 or ChAdOx1-S resulted in a significant reduction in symptomatic covid-19 in older adults, as well as additional protection against severe disease. |
|
-A single dose of either BNT162b2 or ChAdOx1-S provides significant protection against covid-19 as well as additional protection against severe disease for at least six weeks, including protection against the UK variant of concern (B.1.1.7)
– A single dose of either vaccine provides 60-70% protection against symptomatic covid-19 and approximately 80 % protection against hospitalisation. In adults aged 70 and up, BNT162b2 and ChAdOx1-S provide comparable levels of protection. |